{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:32:30Z","timestamp":1759847550687},"reference-count":189,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1097\/fjc.0b013e318165e2e7","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T08:21:05Z","timestamp":1207815665000},"page":"331-351","source":"Crossref","is-referenced-by-count":32,"title":["Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes"],"prefix":"10.1097","volume":"51","author":[{"given":"Madiha","family":"Abdel-Maksoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilisa","family":"Sazonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen W","family":"Gutkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E","family":"Hokanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210208","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R2-1-20210208","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.97.10.946","article-title":"Cholesterol reduction yields clinical benefit: impact of statin trials.","volume":"97","author":"Gould","year":"1998","journal-title":"Circulation"},{"key":"R3-1-20210208","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-1-20210208","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease.","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-1-20210208","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"R6-1-20210208","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"R7-1-20210208","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R8-1-20210208","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archinte.166.7.715","article-title":"The role of fibrates in a statin world.","volume":"166","author":"Bloomfield","year":"2006","journal-title":"Arch Intern Med"},{"key":"R9-1-20210208","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/hc4401.098467","article-title":"Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.","volume":"104","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"R10-1-20210208","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1067\/mhj.2002.130301","article-title":"High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.","volume":"144","author":"Gotto","year":"2002","journal-title":"Am Heart J"},{"key":"R11-1-20210208","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MOL.0b013e32800ff750","article-title":"Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials.","volume":"17","author":"Brown","year":"2006","journal-title":"Curr Opin Lipidology"},{"key":"R12-1-20210208","first-page":"e85","article-title":"Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.","volume":"113","author":"Thom","year":"2006","journal-title":"Circulation"},{"key":"R13-1-20210208","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R14-1-20210208","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-135-6-200109180-00014","article-title":"Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus.","volume":"135","author":"Sniderman","year":"2001","journal-title":"Ann Intern Med"},{"key":"R16-1-20210208","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/diacare.27.10.2444","article-title":"Increasing prevalence of the metabolic syndrome among U.S. adults.","volume":"27","author":"Ford","year":"2004","journal-title":"Diabetes Care"},{"key":"R17-1-20210208","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jama.286.10.1195","article-title":"The continuing epidemics of obesity and diabetes in the United States.","volume":"286","author":"Mokdad","year":"2001","journal-title":"JAMA"},{"key":"R18-1-20210208","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2337\/diacare.23.9.1278","article-title":"Diabetes trends in the U.S.: 1990-1998.","volume":"23","author":"Mokdad","year":"2000","journal-title":"Diabetes Care"},{"key":"R19-1-20210208","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/S0002-8703(99)70037-2","article-title":"Diabetes and ischemic heart disease.","volume":"138","author":"McGuire","year":"1999","journal-title":"Am Heart J"},{"key":"R20-1-20210208","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S0140-6736(97)90025-8","article-title":"What cardiologists need to know about diabetes.","volume":"350","author":"Webster","year":"1997","journal-title":"Lancet"},{"key":"R21-1-20210208","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diacare.22.5.812","article-title":"Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.","volume":"22","author":"Wagner","year":"1999","journal-title":"Diabetes Care"},{"key":"R22-1-20210208","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"R23-1-20210208","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0021-9150(94)90129-5","article-title":"Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.","volume":"106","author":"Griffin","year":"1994","journal-title":"Atherosclerosis"},{"key":"R24-1-20210208","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI116541","article-title":"Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.","volume":"92","author":"Reaven","year":"1993","journal-title":"J Clin Invest"},{"key":"R25-1-20210208","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1001\/jama.1990.03440210043030","article-title":"Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?","volume":"263","author":"Haffner","year":"1990","journal-title":"JAMA"},{"key":"R26-1-20210208","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/01.ATV.9.3.335","article-title":"Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia: study of Utah patients with familial dyslipidemic hypertension.","volume":"9","author":"Hunt","year":"1989","journal-title":"Arteriosclerosis"},{"key":"R27-1-20210208","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1073\/pnas.77.1.604","article-title":"Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].","volume":"77","author":"Sniderman","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"R28-1-20210208","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","author":"Adult Treatment Panel","year":"2002","journal-title":"Circulation"},{"key":"R29-1-20210208","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1152\/physrev.1954.34.3.589","article-title":"Lipoproteins, coronary heart disease, and atherosclerosis.","volume":"34","author":"Gofman","year":"1954","journal-title":"Physiol Rev"},{"key":"R30-1-20210208","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1001\/archinte.1959.00270010010002","article-title":"Serum triglycerides in coronary artery disease.","volume":"103","author":"Albrink","year":"1959","journal-title":"AMA Arch Intern Med"},{"key":"R31-1-20210208","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.0954-6820.1979.tb13526.x","article-title":"Risk factors for myocardial infarction in the Stockholm Prospective Study: a 14-year follow-up focusing on the role of plasma triglycerides and cholesterol.","volume":"206","author":"Carlson","year":"1979","journal-title":"Acta Med Scand"},{"key":"R32-1-20210208","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon.","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"R33-1-20210208","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1161\/01.CIR.97.11.1027","article-title":"Triglyceride: the forgotten risk factor.","volume":"97","author":"Gotto","year":"1998","journal-title":"Circulation"},{"key":"R34-1-20210208","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"R35-1-20210208","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-2002-35403","article-title":"The complex role of triglycerides in cardiovascular disease.","volume":"2","author":"Abdel-Maksoud","year":"2002","journal-title":"Semin Vasc Med"},{"key":"R36-1-20210208","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.","volume":"115","author":"Sawar","year":"2007","journal-title":"Circulation"},{"key":"R37-1-20210208","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/01.CIR.102.2.179","article-title":"Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?","volume":"102","author":"Lemieux","year":"2000","journal-title":"Circulation"},{"key":"R38-1-20210208","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clinthera.2007.05.002","article-title":"Hypertriglyceridemia and cardiovascular risk reduction.","volume":"29","author":"Jacobson","year":"2007","journal-title":"Clin Ther"},{"key":"R39-1-20210208","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archinte.166.7.743","article-title":"Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study.","volume":"166","author":"Tenkanen","year":"2006","journal-title":"Arch Intern Med"},{"key":"R40-1-20210208","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archinte.165.10.1154","article-title":"Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.","volume":"165","author":"Tenenbaum","year":"2005","journal-title":"Arch Intern Med"},{"key":"R41-1-20210208","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R42-1-20210208","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT).","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch Intern Med"},{"key":"R43-1-20210208","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","article-title":"Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).","volume":"26","author":"Robins","year":"2003","journal-title":"Diabetes Care"},{"key":"R44-1-20210208","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"R45-1-20210208","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"R46-1-20210208","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R47-1-20210208","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.100.5.475","article-title":"Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.","volume":"100","author":"Haim","year":"1999","journal-title":"Circulation"},{"issue":"Suppl 1","key":"R48-1-20210208","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1007787713191","article-title":"Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.","volume":"11","author":"de Faire","year":"1997","journal-title":"Cardiovasc Drugs Ther"},{"key":"R49-1-20210208","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1161\/01.ATV.17.12.3633","article-title":"The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles.","volume":"17","author":"Tkac","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R50-1-20210208","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1161\/01.CIR.94.9.2146","article-title":"Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.","volume":"94","author":"Miller","year":"1996","journal-title":"Circulation"},{"key":"R51-1-20210208","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/01.CIR.92.7.1779","article-title":"Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study.","volume":"92","author":"Tenkanen","year":"1995","journal-title":"Circulation"},{"key":"R52-1-20210208","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.90.1.42","article-title":"Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild\/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.","volume":"90","author":"Hodis","year":"1994","journal-title":"Circulation"},{"key":"R53-1-20210208","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/01.CIR.88.6.2762","article-title":"Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events.","volume":"88","author":"Phillips","year":"1993","journal-title":"Circulation"},{"key":"R54-1-20210208","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment.","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"R55-1-20210208","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00000441-199303000-00002","article-title":"Plasma lipid concentrations and subsequent coronary occlusion after a first myocardial infarction: the POSCH Group.","volume":"305","author":"Bissett","year":"1993","journal-title":"Am J Med Sci"},{"key":"R56-1-20210208","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000146898.06923.80","article-title":"Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study.","volume":"110","author":"Marz","year":"2004","journal-title":"Circulation"},{"key":"R57-1-20210208","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9343(01)01123-8","article-title":"Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.","volume":"112","author":"Jonkers","year":"2002","journal-title":"Am J Med"},{"key":"R58-1-20210208","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1995.1687","article-title":"Purification of the human THP-1 monocyte-macrophage triglyceride-rich lipoprotein receptor.","volume":"210","author":"Ramprasad","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"R59-1-20210208","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/S0022-2275(20)41165-4","article-title":"Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells.","volume":"35","author":"Gianturco","year":"1994","journal-title":"J Lipid Res"},{"key":"R60-1-20210208","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.ATV.14.11.1767","article-title":"Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.","volume":"14","author":"Rapp","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"R61-1-20210208","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1161\/01.ATV.14.11.1799","article-title":"Low-density lipoproteins of the postprandial state induce cellular cholesteryl ester accumulation in macrophages.","volume":"14","author":"Lechleitner","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"R62-1-20210208","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.ATV.13.4.472","article-title":"Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia.","volume":"13","author":"Gianturco","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"R63-1-20210208","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000120621.99766.ef","article-title":"European guidelines on cardiovascular disease prevention in clinical practice.","volume":"10","year":"2003","journal-title":"Eur J Cardiovasc Prevent Rehab"},{"key":"R64-1-20210208","doi-asserted-by":"crossref","first-page":"1B","DOI":"10.1016\/S0002-9149(98)00030-7","article-title":"Consensus statement: role of therapy with statins in patients with hypertriglyceridemia.","volume":"81","author":"Grundy","year":"1998","journal-title":"Am J Cardiol"},{"key":"R65-1-20210208","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/01.CIR.0000145615.33955.83","article-title":"Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region.","volume":"110","author":"Patel","year":"2004","journal-title":"Circulation"},{"key":"R66-1-20210208","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.aje.a010013","article-title":"Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.","volume":"150","author":"Clarke","year":"1999","journal-title":"Am J Epidemiol"},{"key":"R67-1-20210208","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.","volume":"335","author":"MacMahon","year":"1990","journal-title":"Lancet"},{"key":"R68-1-20210208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"R69-1-20210208","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"R70-1-20210208","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jama.298.3.336","article-title":"Triglycerides and risk for coronary heart disease.","volume":"298","author":"McBride","year":"2007","journal-title":"JAMA"},{"key":"R71-1-20210208","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.nutr.24.012003.132155","article-title":"The insulin resistance syndrome: definition and dietary approaches to treatment.","volume":"25","author":"Reaven","year":"2005","journal-title":"Annu Rev Nutr"},{"key":"R72-1-20210208","doi-asserted-by":"crossref","first-page":"18B","DOI":"10.1016\/S0002-9149(98)00033-2","article-title":"Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.","volume":"81","author":"Grundy","year":"1998","journal-title":"Am J Cardiol"},{"key":"R73-1-20210208","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0889-8529(03)00073-2","article-title":"Obesity and dyslipidemia.","volume":"32","author":"Howard","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R74-1-20210208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3810\/pgm.2004.09.1584","article-title":"Cardiovascular risk beyond LDL-C levels: other lipids are performers in cholesterol story.","volume":"116","author":"Nash","year":"2004","journal-title":"Postgrad Med"},{"key":"R75-1-20210208","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1161\/01.CIR.94.7.1795","article-title":"Dietary guidelines for healthy American adults: a statement for health professionals from the Nutrition Committee, American Heart Association.","volume":"94","author":"Krause","year":"1996","journal-title":"Circulation"},{"key":"R77-1-20210208","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/01.ATV.0000137119.28893.0b","article-title":"Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation.","volume":"24","author":"Vanschoonbeek","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R78-1-20210208","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism.","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"R79-1-20210208","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00043798-199710000-00011","article-title":"Safety and efficacy of Omacor in severe hypertriglyceridemia.","volume":"4","author":"Harris","year":"1997","journal-title":"J Cardiovasc Risk"},{"key":"R80-1-20210208","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0021-9150(99)00267-1","article-title":"Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.","volume":"148","author":"Calabresi","year":"2000","journal-title":"Atherosclerosis"},{"key":"R81-1-20210208","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/heart.85.5.544","article-title":"An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.","volume":"85","author":"Durrington","year":"2001","journal-title":"Heart"},{"key":"R82-1-20210208","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(01)01114-7","article-title":"N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.","volume":"112","author":"Bucher","year":"2002","journal-title":"Am J Med"},{"key":"R83-1-20210208","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R84-1-20210208","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1001\/archinte.1994.00420230107012","article-title":"The triglyceride issue revisited: findings from the Helsinki Heart Study.","volume":"154","author":"Tenkanen","year":"1994","journal-title":"Arch Intern Med"},{"key":"R85-1-20210208","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.mca.0000224406.60573.8e","article-title":"Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.","volume":"17","author":"Haim","year":"2006","journal-title":"Coronary Artery Disease"},{"key":"R86-1-20210208","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/hc4901.100384","article-title":"Blood lipids and first-ever ischemic stroke\/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.","volume":"104","author":"Tanne","year":"2001","journal-title":"Circulation"},{"key":"R87-1-20210208","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"R88-1-20210208","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/01.CIR.103.23.2828","article-title":"Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).","volume":"103","author":"Rubins","year":"2001","journal-title":"Circulation"},{"key":"R89-1-20210208","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators.","volume":"40","year":"1978","journal-title":"Br Heart J"},{"key":"R90-1-20210208","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"R91-1-20210208","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"R92-1-20210208","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archinte.166.7.737","article-title":"Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.","volume":"166","author":"Tenenbaum","year":"2006","journal-title":"Arch Intern Med"},{"key":"R93-1-20210208","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11883-002-0044-0","article-title":"Update on the role of triglycerides as a risk factor for coronary heart disease.","volume":"4","author":"Miller","year":"2002","journal-title":"Curr Atheroscler Rep"},{"key":"R94-1-20210208","doi-asserted-by":"crossref","first-page":"23L","DOI":"10.1016\/S0002-9149(00)01466-1","article-title":"Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial.","volume":"86","author":"Miller","year":"2000","journal-title":"Am J Cardiol"},{"key":"R95-1-20210208","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/01.CIR.0000012918.84068.43","article-title":"Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.","volume":"105","author":"Sacks","year":"2002","journal-title":"Circulation"},{"key":"R96-1-20210208","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1161\/hc5001.100624","article-title":"Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.","volume":"104","author":"Ballantyne","year":"2001","journal-title":"Circulation"},{"issue":"Suppl","key":"R97-1-20210208","first-page":"II","article-title":"Braunwald E, for the PROVE-IT Investigators. Impact of triglycerides in PROVE-IT TIMI-22: does TG 150 improve CHD risk beyond LDL 70?","volume":"114","author":"Miller","year":"2006","journal-title":"Circulation"},{"key":"R98-1-20210208","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"R99-1-20210208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"R100-1-20210208","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(96)91343-4","article-title":"Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.","volume":"347","author":"Ericsson","year":"1996","journal-title":"Lancet"},{"key":"R101-1-20210208","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0002-9149(97)00626-7","article-title":"Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).","volume":"80","author":"Ericsson","year":"1997","journal-title":"Am J Cardiol"},{"key":"R102-1-20210208","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH).","volume":"323","author":"Buchwald","year":"1990","journal-title":"N Engl J Med"},{"key":"R103-1-20210208","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(87)92734-6","article-title":"Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men.","volume":"2","author":"Krauss","year":"1987","journal-title":"Lancet"},{"key":"R104-1-20210208","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"R105-1-20210208","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.CIR.88.1.20","article-title":"Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound.","volume":"88","author":"Blankenhorn","year":"1993","journal-title":"Circulation"},{"key":"R106-1-20210208","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","article-title":"Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS).","volume":"119","author":"Blankenhorn","year":"1993","journal-title":"Ann Intern Med"},{"key":"R107-1-20210208","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"R108-1-20210208","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R109-1-20210208","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1373\/clinchem.2003.022558","article-title":"Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography.","volume":"49","author":"Frohlich","year":"2003","journal-title":"Clin Chem"},{"key":"R110-1-20210208","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00041433-199508000-00004","article-title":"Triglyceride-rich lipoproteins and the progression of coronary artery disease.","volume":"6","author":"Hodis","year":"1995","journal-title":"Curr Opin Lipidol"},{"key":"R111-1-20210208","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/01.CIR.87.6.1781","article-title":"Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease.","volume":"87","author":"Brown","year":"1993","journal-title":"Circulation"},{"key":"R112-1-20210208","doi-asserted-by":"crossref","first-page":"III","DOI":"10.1161\/01.CIR.0000131511.50734.44","article-title":"Atherogenic lipoprotein particles in atherosclerosis.","volume":"109","author":"Carmena","year":"2004","journal-title":"Circulation"},{"key":"R113-1-20210208","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/hrt.2003.021014","article-title":"Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention.","volume":"90","author":"Morgan","year":"2004","journal-title":"Heart"},{"key":"R114-1-20210208","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0735-1097(88)90356-7","article-title":"Angiographic progression of coronary artery disease and the development of myocardial infarction.","volume":"12","author":"Ambrose","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"R115-1-20210208","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/01.CIR.78.5.1157","article-title":"Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?","volume":"78","author":"Little","year":"1988","journal-title":"Circulation"},{"key":"R116-1-20210208","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/01.CIR.73.4.653","article-title":"Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations.","volume":"73","author":"Brown","year":"1986","journal-title":"Circulation"},{"key":"R117-1-20210208","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0735-1097(86)80455-7","article-title":"Angiographic evolution of coronary artery morphology in unstable angina.","volume":"7","author":"Ambrose","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R118-1-20210208","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/01.CIR.93.1.34","article-title":"Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.","volume":"93","author":"Azen","year":"1996","journal-title":"Circulation"},{"key":"R119-1-20210208","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJM199304293281702","article-title":"Plasma triglyceride level and mortality from coronary heart disease.","volume":"328","author":"Criqui","year":"1993","journal-title":"N Engl J Med"},{"key":"R120-1-20210208","first-page":"111","article-title":"A risk factor for atherosclerosis: triglyceride-rich lipoproteins.","volume":"47","author":"Malloy","year":"2001","journal-title":"Adv Intern Med"},{"key":"R121-1-20210208","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199201233260406","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes (1).","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"R122-1-20210208","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0741-5214(89)90222-X","article-title":"Particle size distribution of lipoproteins from human atherosclerotic plaque: a preliminary report.","volume":"9","author":"Rapp","year":"1989","journal-title":"J Vasc Surg"},{"key":"R123-1-20210208","first-page":"33","article-title":"Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations.","volume":"736","author":"Bradley","year":"1994","journal-title":"J Intern Med Suppl"},{"key":"R124-1-20210208","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1172\/JCI110590","article-title":"Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages.","volume":"70","author":"Gianturco","year":"1982","journal-title":"J Clin Invest"},{"key":"R125-1-20210208","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.ATV.18.2.258","article-title":"Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men.","volume":"18","author":"Byberg","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R126-1-20210208","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.ATV.12.1.19","article-title":"Hypertriglyceridemia and regulation of fibrinolytic activity.","volume":"12","author":"Mussoni","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"R127-1-20210208","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/01.ATV.10.6.1067","article-title":"Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.","volume":"10","author":"Stiko-Rahm","year":"1990","journal-title":"Arteriosclerosis"},{"key":"R128-1-20210208","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0049-3848(99)00089-4","article-title":"Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value.","volume":"96","author":"Chadarevian","year":"1999","journal-title":"Thromb Res"},{"key":"R129-1-20210208","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.ATV.18.1.20","article-title":"Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia.","volume":"18","author":"Eriksson","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R130-1-20210208","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/diacare.21.4.641","article-title":"Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Marys, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.","volume":"21","author":"Elkeles","year":"1998","journal-title":"Diabetes Care"},{"key":"R131-1-20210208","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/bmj.281.6246.973","article-title":"Effect of treatment of hyperlipidaemia on haemostatic variables.","volume":"281","author":"Elkeles","year":"1980","journal-title":"Br Med J"},{"key":"R132-1-20210208","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3476(98)70174-X","article-title":"Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy.","volume":"133","author":"Mietus-Snyder","year":"1998","journal-title":"J Pediatr"},{"key":"R133-1-20210208","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1001\/jama.1997.03550200058032","article-title":"Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal.","volume":"278","author":"Plotnick","year":"1997","journal-title":"JAMA"},{"key":"R134-1-20210208","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jama.1996.03540110036029","article-title":"A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.","volume":"276","author":"Stampfer","year":"1996","journal-title":"JAMA"},{"key":"R135-1-20210208","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0167-5273(99)00107-2","article-title":"The role of small, dense low density lipoprotein (LDL): a new look.","volume":"74","author":"Packard","year":"2000","journal-title":"Int J Cardiol"},{"key":"R136-1-20210208","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0021-9150(94)90108-2","article-title":"Effects of ciprofibrate on LDL metabolism in man.","volume":"108","author":"Gaw","year":"1994","journal-title":"Atherosclerosis"},{"key":"R137-1-20210208","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.ATV.16.6.763","article-title":"Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.","volume":"16","author":"Guerin","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R138-1-20210208","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0021-9150(92)90177-I","article-title":"Differential effects of nicotinic acid in subjects with different LDL subclass patterns.","volume":"95","author":"Superko","year":"1992","journal-title":"Atherosclerosis"},{"key":"R139-1-20210208","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.ATV.13.2.170","article-title":"Effects of simvastatin on apoB metabolism and LDL subfraction distribution.","volume":"13","author":"Gaw","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"R140-1-20210208","doi-asserted-by":"crossref","first-page":"II44","DOI":"10.1002\/clc.4960221409","article-title":"Pharmacologic management of triglycerides.","volume":"22","author":"Hunninghake","year":"1999","journal-title":"Clin Cardiol"},{"key":"R141-1-20210208","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1745-7599.2004.tb00432.x","article-title":"Clinical update on the use of niacin for the treatment of dyslipidemia.","volume":"16","author":"Berra","year":"2004","journal-title":"J Am Acad Nurse Pract"},{"key":"R142-1-20210208","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"key":"R143-1-20210208","doi-asserted-by":"crossref","first-page":"35U","DOI":"10.1016\/S0002-9149(98)00952-7","article-title":"Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.","volume":"82","author":"Goldberg","year":"1998","journal-title":"Am J Cardiol"},{"key":"R144-1-20210208","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia.","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"R145-1-20210208","doi-asserted-by":"crossref","first-page":"252","DOI":"10.7326\/0003-4819-121-4-199408150-00003","article-title":"Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans.","volume":"121","author":"Gray","year":"1994","journal-title":"Ann Intern Med"},{"key":"R146-1-20210208","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial.","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"R147-1-20210208","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"R148-1-20210208","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"R149-1-20210208","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0002-9343(94)90298-4","article-title":"Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.","volume":"97","author":"King","year":"1994","journal-title":"Am J Med"},{"key":"R150-1-20210208","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"key":"R151-1-20210208","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00019501-199604000-00009","article-title":"III. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.","volume":"7","author":"Crouse","year":"1996","journal-title":"Coron Artery Dis"},{"key":"R152-1-20210208","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.96.7.2137","article-title":"Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.","volume":"96","author":"Frick","year":"1997","journal-title":"Circulation"},{"key":"R153-1-20210208","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"R154-1-20210208","doi-asserted-by":"crossref","first-page":"66B","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia.","volume":"81","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"key":"R155-1-20210208","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1994.00420140051007","article-title":"Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial.","volume":"154","author":"Illingworth","year":"1994","journal-title":"Arch Intern Med"},{"key":"R156-1-20210208","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-9343(97)00311-2","article-title":"A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.","volume":"104","author":"McKenney","year":"1998","journal-title":"Am J Med"},{"key":"R157-1-20210208","doi-asserted-by":"crossref","first-page":"52B","DOI":"10.1016\/S0002-9149(98)00039-3","article-title":"Use of niacin, statins, and resins in patients with combined hyperlipidemia.","volume":"81","author":"Brown","year":"1998","journal-title":"Am J Cardio"},{"key":"R158-1-20210208","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R159-1-20210208","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/clc.4960260304","article-title":"A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.","volume":"26","author":"Hunninghake","year":"2003","journal-title":"Clin Cardiol"},{"key":"R160-1-20210208","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0002-9149(03)00318-7","article-title":"Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.","volume":"91","author":"Capuzzi","year":"2003","journal-title":"Am J Cardiol"},{"key":"R161-1-20210208","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9149(94)90005-1","article-title":"Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.","volume":"73","author":"Davignon","year":"1994","journal-title":"Am J Cardiol"},{"key":"R162-1-20210208","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0002-9149(94)90088-4","article-title":"Fluvastatin with and without niacin for hypercholesterolemia.","volume":"74","author":"Jacobson","year":"1994","journal-title":"Am J Cardiol"},{"key":"R163-1-20210208","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9149(00)01410-7","article-title":"Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.","volume":"87","author":"Wolfe","year":"2001","journal-title":"Am J Cardiol"},{"key":"R164-1-20210208","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1345\/aph.1C161","article-title":"Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.","volume":"37","author":"Yim","year":"2003","journal-title":"Ann Pharmacother"},{"key":"R165-1-20210208","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/107424849600100204","article-title":"Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial.","volume":"1","author":"Stein","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R166-1-20210208","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the use and safety of statins.","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"R167-1-20210208","doi-asserted-by":"crossref","first-page":"82U","DOI":"10.1016\/S0002-9149(98)00955-2","article-title":"Treatment of hyperlipidemia with combined niacin-statin regimens.","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"R168-1-20210208","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ecl.2004.11.004","article-title":"The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?","volume":"34","author":"Kendall","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R169-1-20210208","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.2337\/diacare.23.11.1648","article-title":"Preoperative triglycerides predict post-coronary artery bypass graft survival in diabetic patients: a sex analysis.","volume":"23","author":"Sprecher","year":"2000","journal-title":"Diabetes Care"},{"issue":"Suppl A","key":"R170-1-20210208","first-page":"262A","article-title":"Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDLC and diabetes mellitus or impaired fasting glucose [abstract 842-3].","volume":"37","author":"Morse","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"R171-1-20210208","first-page":"636","article-title":"Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project [abstract 3138].","volume":"106","author":"Canner","year":"2002","journal-title":"Circulation"},{"key":"R172-1-20210208","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0002-9149(02)02333-0","article-title":"Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.","volume":"89","author":"Van","year":"2002","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"R173-1-20210208","first-page":"S4","article-title":"Standards of medical care in diabetes-2007.","volume":"30","year":"2007","journal-title":"Diabetes Care"},{"key":"R174-1-20210208","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes.","volume":"28","author":"Ryden","year":"2007","journal-title":"Eur Heart J"},{"key":"R175-1-20210208","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/diab.46.3.433","article-title":"Cardiac and glycemic benefits of troglitazone treatment in NIDDM.","volume":"46","author":"Ghazzi","year":"1997","journal-title":"Diabetes"},{"key":"R176-1-20210208","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0889-8529(18)30323-2","article-title":"Inherited disorders of lipid transport.","volume":"19","author":"Schonfeld","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R177-1-20210208","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/01.ATV.11.1.2","article-title":"Plasma triglyceride and coronary heart disease.","volume":"11","author":"Austin","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"R178-1-20210208","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/oxfordjournals.aje.a113490","article-title":"Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study.","volume":"116","author":"Jacobs","year":"1982","journal-title":"Am J Epidemiol"},{"key":"R179-1-20210208","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/diacare.25.6.989","article-title":"Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study.","volume":"25","author":"Schaefer","year":"2002","journal-title":"Diabetes Care"},{"key":"R180-1-20210208","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.ATV.12.11.1284","article-title":"Change in LDL particle size is associated with change in plasma triglyceride concentration.","volume":"12","author":"McNamara","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"R181-1-20210208","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1185\/030079906X80521","article-title":"The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study.","volume":"22","author":"Miller","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R182-1-20210208","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.","volume":"113","author":"Ortvos","year":"2006","journal-title":"Circulation"},{"key":"R183-1-20210208","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"key":"R184-1-20210208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2337\/diacare.13.2.153","article-title":"Management of dyslipidaemia in NIDDM.","volume":"13","author":"Garg","year":"1990","journal-title":"Diabetes Care"},{"key":"R185-1-20210208","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archinte.165.7.725","article-title":"Effect of different antilipidemic agents and diets on mortality: a systemic review.","volume":"165","author":"Studer","year":"2005","journal-title":"Arch Intern Med"},{"key":"R186-1-20210208","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2003.10.003","article-title":"Serum homocysteine concentrations, gemfibrozil treatment and progression of coronary atherosclerosis.","volume":"172","author":"Syvanne","year":"2004","journal-title":"Atherosclerosis"},{"key":"R187-1-20210208","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0140-6736(92)92588-7","article-title":"WHO clofibrate\/cholesterol trial: clarifications.","volume":"340","author":"Heady","year":"1992","journal-title":"Lancet"},{"key":"R188-1-20210208","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R189-1-20210208","first-page":"600","article-title":"WHO Cooperative Trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up.","volume":"2","year":"1984","journal-title":"Lancet"},{"key":"R190-1-20210208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0167-5273(01)00625-8","article-title":"Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.","volume":"82","author":"Rizos","year":"2002","journal-title":"Int J Cardiol"},{"key":"R191-1-20210208","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00005344-200804000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T01:44:11Z","timestamp":1618364651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-200804000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":189,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0b013e318165e2e7","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}